News | Contrast Media | December 09, 2016

Bracco Diagnostics Highlights Contrast Media Milestones at RSNA 2016

Company received several key FDA approvals, including first contrast agent for liver ultrasound in adult and pediatric patients, first syringe-less power injector

 

contrast media

At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased a review of key milestones the company has achieved this year in diagnostic imaging and contrast media.

The following summary provides a snapshot of major milestones impacting Bracco this year:

  • U.S. Food and Drug Administration (FDA) approval and recent launch of the first and only syringe-less power injector in the United States, designed to streamline workflow and improve patient care for computed tomography (CT);
  • The company received the first FDA approval for contrast-enhanced ultrasonography of the liver in adult and pediatric patients — the first ultrasound contrast agent approved for use in pediatrics in the world. This year, the Centers for Medicare & Medicaid Services approved coverage and coding for abdominal ultrasound with contrast under the Hospital Outpatient Prospective Payment System;
  • The company received the first and only FDA approvals of two of its barium-based products (one for CT; one for contrast radiography);
  • The company received an Innovative Technology Designation from Vizient for its injectable suspension for contrast echocardiography; and
  • Virtual colonoscopy received the highest grade from the U.S. Preventive Services Task Force as an alternative screening tool in detecting colorectal cancer. The recommendation was made after the task force found that CT colonography was proven to reduce the incidence and mortality of colorectal cancer, the second deadliest cancer in the U.S. Bracco markets the latest CO2 insufflator and a stool marker, or "fecal tagging" agent, for CT colonoscopy.

For more information: www.imaging.bracco.com/us-en

Related Content

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a ver
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
August 14, 2020 — The U.S.
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...